Timing is everything: new study aims to perfect miscarriage treatment

NCT ID NCT07506512

Not yet recruiting Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the best time interval between two medications, mifepristone and misoprostol, for managing early pregnancy loss. Researchers will follow 1,000 participants to see which timing leads to the highest success rate with fewer side effects. The goal is to improve treatment and satisfaction for those experiencing this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mifepristone and misoprostol
What this could lead to: If successful, this could establish a standard timing for these medications, improving treatment success and patient satisfaction for early pregnancy loss.
What could go wrong: This is a Phase 3 trial, but it's still testing timing, not a new drug. Results may vary by individual, and there are risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY PREGNANCY LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Abortion, Spontaneous

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EARLY PREGNANCY LOSS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.